Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare. Featured Guests: Dame Sally Davies, UK Special Envoy for Antimicrobial Resistance Daniel Gallego, President of the European Kidney Patient Federation Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer Subha Madhavan, Vice President & Head of AI/ML, Quantitative & Digital Sciences, Global Biometrics & Data Management Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development. Featured Guests: Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich Lei Zhang, Executive Director of Medicinal Chemistry, Pfizer Medicine Design Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance. Featured Guests: Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich Ranjit Kumble, Vice President of Enterprise Data Science and Advanced Analytics, Pfizer Marinka Zitnik, Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Co-founder, Therapeutics Data Commons Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence. Featured Guests: Adrian Egli, Director, Institute of Medical Microbiology, University of Zurich Jay Purdy, Vice President and Therapeutic Area Lead, Global Medical Affairs, Pfizer Antibacterial and Antifungal Programs Mary Lynne Van Poelgeest-Pomfret, President, World Federation of Incontinence and Pelvic Problems Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon! Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials? Featured Guests: Laurie, Breast Cancer Clinical Trial Participant Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University Julia Perkins Smith, Global Clinical Lead, Pfizer Jamil Rivers, CEO, Chrysalis Initiative Additional Resources: pfizerclinicaltrials.com/oncology pfizerclinicaltrials.com pfizerestudiosclinicos.com

Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer. Featured Guests: Martha Carlson, Breast Cancer Advocate & Writer Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University Jeff Settleman, Chief Scientific Officer, Pfizer Oncology

Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!

Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society. Featuring guests: Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders Erik Paulsen, Chair, Institute for Gene Therapies Karolina Hanslik, Former Senior Project Manager, EURORDIS Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer Paige Bischoff, Senior Vice President, Global Public Affairs, Alliance for Regenerative Medicine Paolo Morgese, EU Director, Market Access, Alliance for Regenerative Medicine Reda Guiha, IDM Regional President, Rare Disease, Pfizer Simone Boselli, Director, Public Affairs, EURORDIS Tomislav Sokol, Member of European Parliament

As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them. Featuring guests: Bert Bruce, Regional President, North America, Rare Disease, Pfizer Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders Emily Crossley, Chief Executive Officer, Duchenne UK Erik Paulsen, Chair, Institute for Gene Therapies Karolina Hanslik, Senior Project Manager, EURORDIS Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer Suneet Varma, Global President, Rare Disease, Pfizer Tomislav Sokol, Member of European Parliament

Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients. Featuring guests: Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer Emily Crossley, Chief Executive Officer, Duchenne UK Erik Paulsen, Chair, Institute for Gene Therapies Professor John Rasko, Clinical Haematologist & Trial Investigator, University of Sydney Simone Boselli, Director, Public Affairs, EURORDIS Suneet Varma, Global President, Rare Disease, Pfizer

Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy. Featuring guests: Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, Pfizer Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders Laurence Woollard, Director, On The Pulse Consultancy Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy.

In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures? Featuring guests: Bert Bruce, Regional President, North America, Rare Disease, Pfizer Bob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer